Beyond the Surface: Tailored Solutions for Tear Evaporation in Meibomian Gland Dysfunction : Episode 5
Managing Evaporative Dry Eye with New FDA-Approved Therapy
Experts provide clinical insights on the first FDA-approved treatment for evaporative dry eye, perfluorohexyloctane ophthalmic solution (MEIBO).
EP: 1.Overview of MGD and Its Causes
EP: 2.Differentiating Aqueous vs Evaporative Dry Eye
EP: 3.Long-Term Consequences of Untreated MGD
EP: 4.Factors to Consider in Treatment Selection for MGD
Now Viewing
EP: 5.Managing Evaporative Dry Eye with New FDA-Approved Therapy
EP: 6.Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye
EP: 7.Combining In-Office and At-Home Therapies
EP: 8.Clinical Case Scenario: Management Strategies for MGD and Key Takeaways
Video content above is prompted by the following questions:
- We now have the first FDA-approved treatment for evaporative dry eye [perfluorohexyloctane ophthalmic solution (MIEBO)]. What is significant about this new treatment?
- Why do we need to target evaporative dry eye specifically?
Recent Videos
Related Content
